Comparison of results of salvage therapy in adult acute myelogenous leukemia.
The results of initial salvage therapy for refractory and relapsed acute myelogenous leukemia for patients treated between 1973 and 1986 have been evaluated. There was no significant improvement in complete remission (CR) rate and survival in patients treated between 1973 and 1980, and the second group between 1981 and 1986. The remission duration was slightly longer in the second time period than in the initial time period. A number of factors were associated with the probability of achieving a CR. The major factors were the age of the patient, duration of the initial CR, liver function test abnormalities, and white blood cell count.
D000328:Adult; D000677:Amsacrine / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D004317:Doxorubicin / Q000008:administration & dosage; D004341:Drug Evaluation; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008942:Mitoxantrone / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D011446:Prospective Studies; D012008:Recurrence; D012044:Regression Analysis; D012189:Retrospective Studies; D014750:Vincristine / Q000008:administration & dosage
D000677:Amsacrine; D003561:Cytarabine; D014750:Vincristine; D004317:Doxorubicin; D008942:Mitoxantrone; C002205:zorubicin; D011241:Prednisone; D003630:Daunorubicin